 Connection
Michael Bristow to Risk
This is a "connection" page, showing publications Michael Bristow has written about Risk.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.069 |
|
|
|
-
Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004 May 20; 350(21):2140-50.
Score: 0.046
-
Bristow MR. Toxic cardiomyopathy due to doxorubicin. Hosp Pract (Off Ed). 1982 Dec; 17(12):101-8, 110-1.
Score: 0.010
-
Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23; 334(21):1349-55.
Score: 0.007
-
Torti FM, Bristow MR, Howes AE, Aston D, Stockdale FE, Carter SK, Kohler M, Brown BW, Billingham ME. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med. 1983 Dec; 99(6):745-9.
Score: 0.003
-
McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J. 1983 Nov; 106(5 Pt 1):1048-56.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|